James B. Koprich, Ph.D. - Publications

Affiliations: 
Toronto Western Research Institute, Toronto, Ontario, Canada 
Area:
Parkinson's disease therapeutics

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. Molecular Neurobiology. PMID 25972237 DOI: 10.1007/s12035-015-9173-7  0.8
2015 Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behavioural Pharmacology. 26: 101-8. PMID 25303957 DOI: 10.1097/FBP.0000000000000096  0.8
2014 Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. 82: 76-87. PMID 24447715 DOI: 10.1016/j.neuropharm.2014.01.012  0.8
2013 Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology. 73: 337-47. PMID 23770260 DOI: 10.1016/j.neuropharm.2013.06.005  0.8
2013 Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacological Reviews. 65: 171-222. PMID 23319549 DOI: 10.1124/pr.111.005678  0.8
2013 Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 151-6. PMID 23306217 DOI: 10.1016/j.pnpbp.2012.12.008  0.8
2013 Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. The European Journal of Neuroscience. 37: 831-8. PMID 23281915 DOI: 10.1111/ejn.12093  0.8
2012 Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology. 63: 829-36. PMID 22722022 DOI: 10.1016/j.neuropharm.2012.06.012  0.8
2012 Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 342: 576-85. PMID 22619253 DOI: 10.1124/jpet.112.195693  0.8
2012 Thompson VB, Koprich JB, Chen EY, Kordower JH, Terpstra BT, Lipton JW. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicology and Teratology. 34: 206-13. PMID 21978916 DOI: 10.1016/j.ntt.2011.09.005  0.8
2012 Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of Aging. 33: 207.e9-19. PMID 21051107 DOI: 10.1016/j.neurobiolaging.2010.09.011  0.8
2011 Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7190-8. PMID 21562283 DOI: 10.1523/JNEUROSCI.1171-11.2011  0.8
2011 Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1225-33. PMID 21465551 DOI: 10.1002/mds.23631  0.8
2011 Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Plos One. 6: e17698. PMID 21408191 DOI: 10.1371/journal.pone.0017698  0.8
2010 Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 16091-101. PMID 21123556 DOI: 10.1523/JNEUROSCI.2400-10.2010  0.8
2010 Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Molecular Neurodegeneration. 5: 43. PMID 21029459 DOI: 10.1186/1750-1326-5-43  0.8
2009 Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proceedings of the National Academy of Sciences of the United States of America. 106: 22474-9. PMID 20007772 DOI: 10.1073/pnas.0912193106  0.8
2009 Emborg ME, Moirano J, Raschke J, Bondarenko V, Zufferey R, Peng S, Ebert AD, Joers V, Roitberg B, Holden JE, Koprich J, Lipton J, Kordower JH, Aebischer P. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiology of Disease. 36: 303-11. PMID 19660547 DOI: 10.1016/j.nbd.2009.07.022  0.8
2009 Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM. New insights into the organization of the basal ganglia. Current Neurology and Neuroscience Reports. 9: 298-304. PMID 19515282 DOI: 10.1007/s11910-009-0045-2  0.8
2009 Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 3365-73. PMID 19295143 DOI: 10.1523/JNEUROSCI.5427-08.2009  0.8
2008 Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. Journal of Neuroinflammation. 5: 8. PMID 18304357 DOI: 10.1186/1742-2094-5-8  0.8
2007 Chung CY, Koprich JB, Endo S, Isacson O. An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 8314-23. PMID 17670978 DOI: 10.1523/JNEUROSCI.1972-07.2007  0.8
2007 He B, Counts SE, Perez SE, Hohmann JG, Koprich JB, Lipton JW, Steiner RA, Crawley JN, Mufson EJ. Corrigendum to "ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice" [Neuroscience 133 (2005) 371-380] (DOI:10.1016/j.neuroscience.2005.01.068) Neuroscience. 144: 1544. DOI: 10.1016/j.neuroscience.2006.12.005  0.8
2006 Emborg ME, Roitberg BZ, Moirano J, Zufferey R, Ebert AD, Joers V, Holden J, Converse AK, Koprich JB, Kordower JH, Aebischer P. Lentiviral Delivery of Glial Cell Line-derived Neurotrophic Factor in Aged 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Rhesus Monkeys 883. Neurosurgery. 59: 481-482. PMID 28180727 DOI: 10.1227/01.NEU.0000309933.75950.48  0.52
2006 Campbell NG, Koprich JB, Kanaan NM, Lipton JW. MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment. Neurotoxicology and Teratology. 28: 459-65. PMID 16905291 DOI: 10.1016/j.ntt.2006.05.006  0.8
2005 Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 10220-9. PMID 16267229 DOI: 10.1523/JNEUROSCI.2773-05.2005  0.8
2005 He B, Counts SE, Perez SE, Hohmann JG, Koprich JB, Lipton JW, Steiner RA, Crawley JN, Mufson EJ. Ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice. Neuroscience. 133: 371-80. PMID 15885921 DOI: 10.1016/j.neuroscience.2005.01.068  0.8
2004 Krenitsky TA, Dillberger J, Zotova E, Arezzo JC, Koprich JB, Mortazavi F, Gates TA, Dunbar GL. KP544, a nerve growth factor amplifier: Pharmacokinetics, safety, and efficacy in the rat Drug Development Research. 62: 60-70. DOI: 10.1002/ddr.10384  0.8
2003 Koprich JB, Campbell NG, Lipton JW. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Research. Developmental Brain Research. 147: 177-82. PMID 14741762 DOI: 10.1016/S0165-3806(03)00219-0  0.8
2003 Lipton JW, Gyawali S, Borys ED, Koprich JB, Ptaszny M, McGuire SO. Prenatal cocaine administration increases glutathione and alpha-tocopherol oxidation in fetal rat brain. Brain Research. Developmental Brain Research. 147: 77-84. PMID 14741753 DOI: 10.1016/j.devbrainres.2003.08.006  0.8
2003 Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicology and Teratology. 25: 509-17. PMID 12972064 DOI: 10.1016/S0892-0362(03)00091-6  0.8
Show low-probability matches.